Topic:

R&D

Latest Headlines

Latest Headlines

Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro

Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and its antibody-drug conjugates and bispecifics. And Celgene is expanding their collaboration to include immuno-oncology drugs, the hottest R&D field in biotech.

J&J heads to Texas with its R&D farm system, scouting for biotech startups

Johnson & Johnson is expanding its network of biopharma incubators, taking to Texas with a plan to host as many as 50 local biotech startups.

Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will come too late

As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.

Encapsulation of fecal matter achieved for treatment of infected colons

Fecal microbiota transplantation enables the reconstitution of gut bacteria, and has been proven effective to treat Clostridium difficile infections of the colon. But, as you can imagine, the nature of the active ingredient presents a tough drug delivery challenge. Luckily, the field is advancing.

Regulus soars on promising--but early--results for its hep C contender

Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.

J&J gives the Ebola vaccine push a $200M boost

With several players now in the race toward a vaccine for Ebola, Johnson & Johnson says it is ramping up development efforts toward its own program, devoting $200 million to the cause.

Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain

Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.

Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner

As the promise of harnessing the immune system to fight cancer grabs headlines around the industry, venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics, a Cambridge, MA, startup with a hybrid approach to the field.

TesoRx licenses oral low-T drug to Aspen amid FDA crackdown

While the testosterone therapy field is under fire from government regulators, Menlo Park, CA-based TesoRx is licensing its oral-testosterone replacement therapy to a subsidiary of South African generics maker Aspen Pharmacare.

Charles River debuts new testing tech for quality control

Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.